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Abstract: Structural selectivity – in fact, the lack thereof – has been invoked as an explana-
tion for the failure of matrix metalloproteinase (MMP) inhibitors as oncology drugs. However, 
functional selectivity is needed to develop a good drug. In addition, many drugs (including 
in oncology) act by interfering with signaling functions. The present market of successful 
biologicals contains many monoclonal antibodies, such as signaling inhibitors, with antitumor 
necrosis factor (anti-TNF) being the flagship of an armada. However, aside from its many 
pathogenic functions, TNF also plays physiological (ie, beneficial) roles. As long as the inhibi-
tion of detrimental functions supersedes the negative side effects, anti-TNF will be used. For 
such reasons, it is critical to know all the functions of MMPs, ideally before inhibitors are used 
as drugs. Here, we briefly summarize the known catalytic MMP functions and focus on the 
noncatalytic roles of these proteins, with an emphasis on their signaling effects. Indeed, recent 
studies have addressed the biology of multimolecular signaling complexes containing MMPs 
and the tissue inhibitors of metalloproteinases. These complexes are observed in solution 
(eg, as heteromers or homomultimers) and at the cell surfaces (eg, as docking complexes and 
signaling receptors). Consequently, a good understanding of the broader contexts – from the 
molecular, to the cellular and tissue levels – in which such molecular complexes operate will 
provide essential insights into direct new drug developments. This is exemplified with clinical 
and recent preclinical successes.
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Introduction
The success of a molecule often depends on its name and, even with an attractive name, 
one can be wrong in terms of its applications. A few decades ago, two similar molecules 
with related receptor molecules, converging signal transduction cascades, and matching 
biological effects were identified and named tumor necrosis factor (TNF) and lympho-
toxin (LT). “TNF” alluded to the beneficial effect of destroying cancer cells,1 whereas 
“LT” emphasized toxicity.2 Meanwhile, TNF has been cited about 150,000 times in the 
PubMed data library, whereas LT is creeping toward 4,000 citations. In addition, these 
names yielded the wrong perceptions. Indeed, it was the inhibition of TNF, in the 
form of neutralizing monoclonal antibodies and resulting in immunosuppression or 
toxicity toward autoantigen-specific T-lymphocytes, that entered clinical practice.3 
Similar simple reasoning can be made for matrix metalloproteinases (MMPs). The 
medical literature contains an increasing number of manuscripts illustrating that the 
launched concepts and clinical uses of MMP inhibitors against cancer cell invasion 
and metastasis were too simple and, in fact, wrong.4–7
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Although some activities of MMPs were reflected by 
their functional names, such as collagenases, stromelysins, 
gelatinases, and membrane-type (MT)-MMPs (Figure 1), we 
should humbly accept that their most recent nomenclature is 
not appealing, sometimes confusing for novices (where are 
MMP-4, MMP-5, and MMP-6?), and certainly not reflecting 
their noncatalytic functions. The main biochemical (domain 
structure, mechanism of substrate proteolysis, and regulation 
of catalysis at the protein level) and biological characteris-
tics of human MMPs as enzymes have been the subject of 
excellent reviews on cancer8–10 and on inflammatory and 
vascular diseases.11–14 Catalytic functions are also illustrated 
by manuscripts on the processing of substrates by specific 
enzymes.15–17 In addition, useful reviews about membrane-
bound and intracellular MMP substrates exist.18,19
Recent developments of enzyme-based degradomics – ie, 
the definition of all substrates of one specific enzyme20,21 – and 
substrate-based reverse degradomics, in which all proteases act-
ing on a single substrate are defined,22 illustrate renewed interests 
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Figure 1 Schematic drawing depicting the domain structure of MMPs.
Notes: The signal peptide guides the MMP through the rough endoplasmic reticulum during synthesis and is cleaved off during secretion by the docking enzyme; the SH 
propeptide domain maintains the enzyme inactive by blocking the catalytic site, and it is removed or unfolded for MMP activation; the catalytic domain contains the active site 
of the enzyme and the Zn2+-binding segment. This basic structure is contained in MMP-7 and MMP-26 (matrilysins). MMP-2 and MMP-9 contain three fibronectin-like type 
II repeats between the active site and the Zn2+-binding segment, and these are responsible for the gelatin-binding property. MMP-9 contains an additional O-glycosylated 
region, which confers flexibility to the molecule. Except for MMP-7 and MMP-26, all other MMPs contain a carboxy-terminal hemopexin domain, which confers specificity and 
interacts with many ligands and receptors. The hemopexin and catalytic domains are connected by a small hinge region. MT-MMPs have an additional transmembrane domain 
and a short cytoplasmic tail or a GPI linkage, which anchor MT-MMPs to the cell membrane.
Abbreviations: MMP, matrix metalloproteinase; SH, sulfhydryl-containing; GPI, glycosylphosphatidylinositol; MT, membrane-type.
in proteolysis and its complexities. These approaches led to a 
conceptual change: from proteases acting in linear cascades (eg, 
clotting, fibrinolysis, and complement cascades)23 to the protease 
network, which was first elaborated in detail for all known 
interactions between serine proteases and MMPs in 200224 and 
further developed into the protease net17,21,25 or protease web.7 
The network concept makes us better understand why the entire 
system is complex. However, such concepts are currently also 
used to develop signaling inhibitors by the definition of the 
most critical nodes and connections in signaling networks. 
Consequently, real hope exists that, by (reverse) degradomics 
analysis and by deciphering the MMP network nodes, inhibitors 
of specific key proteases may become useful drugs.
Here, however, the emphasis will be on the noncatalytic 
functions of mammalian MMPs. These functions are based on 
and include covalent and noncovalent interactions with het-
eromers and homomultimers, which bind onto cell surfaces 
and soluble molecular complexes, as well as interactions with 
cognate receptors with ensuing signaling events. Finally, we 
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briefly address how “cascadic signaling” in life-threatening 
conditions involves MMPs and how such knowledge may 
give new turns towards the use of existing MMP inhibitors, 
developed against cancer, to become life-saving drugs for 
lethal inflammatory conditions, such as sepsis, endotoxine-
mia and superantigen-induced shock syndromes.
Structural features  
of MMPs – a brief overview
The primary structure of MMPs has been addressed in 
previous reviews.12,14,18,26 However, it is the tridimensional 
structure of glycoproteins that determines their functions. 
Although the crystal structures of some MMPs are known 
and were compiled long ago in a seminal review that also 
addressed molecular evolution,27 the determination of the 
secondary and tertiary structures of a number of MMPs 
remains a challenge in structural biology. For example, the 
full-size structures of MMP-9, as the most studied proteinase 
in the MMP family,28 and of all MT-MMPs, are not known. 
Therefore, theoretical models are presently used as a surrogate 
with the aim of understanding the interactions with substrates, 
inhibitors,27 receptors,29–31 proteoglycans,32 and other MMP 
ligands.33 As an example, full-size MMP-9 occurs in multiple 
forms: monomers; homomultimers; and  heteromers.28 These 
molecular forms are endowed with different functions, as we 
recently demonstrated for the monomeric and trimeric form 
of MMP-9.34 In addition, when produced by specific cells, 
MMP-9 forms a covalent heteromer with neutrophil gelatinase 
B-associated lipocalin. This soluble form of MMP-9 links the 
functionalities of MMP-9 with those of the lipocalin.28
All MMPs are composed of several structural domains 
with distinct functions and are synthesized as catalytically 
inactive proforms (Figure 1). The simplest structure is repre-
sented by matrilysins (MMP-7, MMP-26), which contain the 
signal peptide and propeptide, as well as the catalytic domain. 
The rest of the MMPs contain a carboxy-terminal hemopexin 
domain (also known as PEX), which is bound to the catalytic 
part of the molecule by the so-called hinge region. Because 
of the focus of this review, we will dedicate a separate sec-
tion to the hemopexin domain. MMP-2 and MMP-9 contain 
an additional region consisting of fibronectin-like repeats, 
responsible for the gelatin-binding activity of these MMPs. 
MMP-9 also contains a unique O-glycosylated domain,31 
which confers flexibility to the molecule and appears to 
be indispensable for MMP-9 functions.28 The MT-MMPs 
contain either a glycosylphosphatidylinositol membrane 
anchor or a transmembrane and cytoplasmic domain 
(Figure 1). Both types of anchors serve to localize MT-MMPs 
to cell surfaces. The catalytic and carboxy-terminal domains 
(hemopexin and cytoplasmic) are therefore separate entities 
in the MMP molecule and, as we will define, they perform 
different and crucial functions in MMPs.
Targeting the catalytic domain  
of MMPs: from twice thinking small 
to integration and considering big
Originally, the catalytic function of proteases, such as plasmi-
nogen activators and MMPs, in cancer cell invasion and metas-
tasis was viewed as the sole property of these  glycoproteins. 
Hence, their inhibition was regarded as  possible, preferably 
with orally active small drugs. This simple reasoning boosted 
enormous research on these proteases and generated excel-
lent inhibitors. The integration of basic, preclinical, and 
clinical studies, however, showed that this view was narrow-
sighted and that the developed drugs, by their small sizes, 
interacted with many proteases and hence possessed poor 
selectivity and yielded side effects during their use as cancer 
therapeutics.4–8,10–14 We and others tried to counter these nega-
tive results with a more optimistic and positive view because 
these small drugs may become excellent candidates for the 
treatment of life-threatening acute inflammation, in which side 
effects may be of secondary importance.12–14
The problem of low selectivity was considered, and large 
molecules – namely, inhibitory monoclonal antibodies – were 
also developed into inhibitors of MMP catalysis.35,36 It was 
demonstrated long ago that with such large-sized inhibi-
tors, it is possible to reach high selectivity. For instance, the 
monoclonal antibody REGA-3G12 was the first reagent 
with selective inhibition of activated MMP-9 (and not 
of MMP-2).36 In a subsequent study, the interaction site 
between REGA-3G12 and its antigen MMP-9 was studied 
and found to consist of part of the catalytic site and an area 
aside this.37 These findings are in line with the concept of 
exosite interactions to obtain higher selectivity, as nicely 
promoted by several studies.38–40 These studies are examples 
of the integration of structural data and thinking beyond the 
small catalytic pocket of a proteolytic enzyme. In addition, 
the generation of activity-neutralizing monoclonal antibod-
ies against MMPs has recently been further developed and 
the obtained reagents have been preclinically used to treat 
experimentally-induced colitis in mice.40 In this case, and if 
we think big about novel treatments of (invasive) cancer, the 
successful monoclonal antibody treatment of an inflamma-
tory disease in a mouse model will hopefully pave the way 
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to new successes when such, or other, catalytic inhibitors are 
tested in cancer models.41
Noncatalytic functions of MMPs
An increasing number of studies are demonstrating that MMPs 
can also perform functions independently of their proteolytic 
activity, thus providing additional ways by which MMPs may 
contribute to pathology. Nonproteolytic functions mostly rely 
on the localization of MMPs at the cell surface which, in the 
case of MT-MMPs, is mediated by their transmembrane and 
cytoplasmic domains or by their glycosylphosphatidylinositol 
membrane anchor (Figure 1). MMPs devoid of these struc-
tures can still bind to the cell surface via specific receptors; 
among these are the integrins and CD44 (Table 1).29–31,42,43 
This receptor-binding function, which generally requires the 
MMP hemopexin domain, was thought to exclusively serve to 
activate/inhibit MMPs and to localize their catalytic activity 
to the pericellular  environment. However, numerous recent 
evidences are changing this concept and supporting the fact 
that MMPs can also induce cell signaling upon interaction 
with their cell surface receptors.
Nonproteolytic functions  
of MMP-1, MMP-2, and MMP-3
Initial studies by Conant et al44 showed that MMP-1 bind-
ing to α2β1 integrin in neural cells and monocytes elicits 
a signaling pathway sensitive to pertussis toxin and results 
in the release of MMP-9. The same effect is observed 
when proMMP-1 is used or by inhibiting MMP-1 with 
GM-6001, indicating that the enzymatic activity of MMP-1 
is not required. Additionally, the proMMP-1/α2β1 integrin 
interaction also induces Akt dephosphorylation and neuron 
cell death.45 This effect is blocked by an antibody against 
α2 integrin and it is independent of the MMP-1 proteolytic 
activity since 1) total Akt levels remain unchanged, and 2) 
batimastat, an inhibitor of the catalytic activity of MMP-1, 
does not prevent proMMP-1-induced Akt  dephosphorylation. 
Similarly, proMMP-2 interaction with αVβ3 integrin on 
lung adenocarcinoma cells induces vascular endothelial 
growth factor (VEGF) expression via activation of PI3K/
Akt/HIF-1α, leading to increased angiogenesis.46 In MMP-3, 
the hemopexin domain binds to the chaperone heat-shock 
protein 90β (HSP90β) extracellularly, and this is critical for 
mouse mammary epithelial cell invasion.47 Using several 
structural mutants of MMP-3, the authors demonstrate that 
the hemopexin domain is required for the invasive function 
of MMP-3 during branching morphogenesis. This is also 
demonstrated in primary organoids of the mammary gland. 
The mechanism by which MMP-3 overexpression induces 
mammary tumors in transgenic mice was elegantly demon-
strated by Kessenbrock et al.48 Using lentiviral constructs 
containing MMP-3, a proteolytically inactive mutant, or the 
MMP-3 PEX domain, these authors demonstrate that these 
three proteins induce a hyperbranching phenotype equally 
Table 1 Molecular interactions and biological effects involving noncatalytic MMP domains
MMP Receptor/ligand Cell type Biological effect References
MMP-1 α2β1 integrin Neural cells, monocytes Release of MMP-9, Akt dephosphorylation 44,45
MMP-2 αvβ3 integrin Lung adenocarcinoma Increased veGF expression and angiogenesis 46
MMP-3 HSP90β 
wnt5b
Mammary gland epithelial cells Cell invasion, branching morphogenesis 
wnt5 inactivation, hyperbranching phenotype
47,48
MMP-9 LRP-1 
LRP-2/megalin
Schwann cells, COS-1 
Yolk sac sarcoma cells (BN16)
eRK1/2 and Akt activation, cell migration, catabolism 
MMP-9 endocytosis and catabolism
31
IGF-1, eGFR, PDGFR Schwann cells Ras/Raf/MeK–eRK regulation, phenotypic remodeling 50
α4β1 integrin, CD44v Chronic lymphocytic leukemia MMP-9 cell surface localization, activation of the  
Lyn/STAT3/Mcl-1 pathway, cell migration/arrest, cell survival
54,55,57
CD44 Breast carcinoma eGFR activation, cell migration 51
Melanoma Actomyosin contractility, rounded amoeboid, cell invasion 58
CSPG Monocytic cells proMMP-9/CSPG complex formation, prevention of TIMP-1  
binding to proMMP-9, weaker binding to gelatin
32
Ku protein Monocytes MMP-9 internalization, cell invasion 33
MMP-14 TIMP-2 Breast carcinoma, fibrosarcoma eRK1/2 activation, cell proliferation, and migration 61,62
HIF-1α Macrophages Stimulation of glycolysis and ATP production 64
Myeloid cells Rac1 activation, lamellipodia activity 
Cell motility, cell fusion
65
β1 integrin Mammary epithelial cells eRK activation, branching morphogenesis 66
Abbreviations: MMP, matrix metalloproteinase; veGF, vascular endothelial growth factor; LRP, lipoprotein receptor-related protein; eRK, extracellular signal-regulated 
kinase; IGF, insulin-like growth factor; PDGFR, platelet-derived growth factor receptors; eGFR, epidermal growth factor receptor; CSPG, chondroitin sulfate proteoglycans; 
TIMP, tissue inhibitor of metalloproteinase; ATP, adenosine triphosphate; HIF, hypoxia-inducible factor; MeK, mitogen-activated protein kinase kinase; STAT3, signal 
transducer and activator of transcription 3; Mcl-1, myeloid cell leukemia-1.
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well upon implanting into mammary fat pads. This was due 
to the specific interaction of the MMP-3 PEX domain with 
the extracellular noncanonical Wnt ligand Wnt5b, resulting 
in its inactivation. MMP-3 thus regulates Wnt signaling and 
adult epithelial stem cell function via the PEX domain in a 
noncatalytic manner.
Nonproteolytic functions of MMP-9
Several reports have addressed the notion of intracellular sig-
naling induced upon MMP-9’s interaction with its cell surface 
receptors. Binding of MMP-9 or a fusion protein containing 
the hemopexin domain of MMP-9 (PEX9), coupled to GFP, to 
the low-density lipoprotein receptor-related protein (LRP-1) 
in Schwann cells activates extracellular signal-regulated 
kinase (ERK)1/2 and Akt, and it promotes cell migration.49 
This effect is blocked by inhibiting MMP-9 binding either 
by LRP-1 gene silencing or by an antibody targeting PEX9. 
The related protein LRP-2/megalin is also a receptor for 
MMP-9 in epithelial cells and mediates its endocytosis and 
catabolism (Table 1).31 MMP-9 can also bind to insulin-like 
growth factor-1, ERbB, and platelet-derived growth factor 
receptors, resulting in the regulation of Ras/Raf/MEK–ERK 
pathways and the controlling of critical trophic signals and 
phenotypic remodeling of Schwann cells.50 Whether regula-
tion of these pathways occurs via regulatory proteolysis or by 
direct receptor binding  (nonproteolytic) was not determined. 
Dufour et al51 demonstrated that transfection of COS-1 cells 
with MMP-2, MMP-9, or a catalytically inactive mutant of 
MMP-9 enhances cell migration. This effect requires the 
PEX9 domain, as well as MAPK and PI3K activities, but the 
specific mechanism involved was not elucidated. proMMP-9 
has also been shown to interact with the I domain of αLβ2 
and αMβ2 integrins on leukocytes, and these proMMP-9/β2 
integrin complexes are important for cell migration.52,53 This 
interaction involves the catalytic region of proMMP-9 rather 
than the hemopexin domain, and it is not known whether 
it results in intracellular signaling. Our group has shown 
that binding of proMMP-9 to α4β1 integrin and 190 kDa 
CD44v, its docking receptors in chronic lymphocytic leu-
kemia (CLL) cells,54 induces a signaling pathway that leads 
to malignant cell survival.55 This pathway consists of Lyn 
kinase activation, STAT3 phosphorylation, and upregula-
tion of the antiapoptotic protein Mcl-1, a member of the 
Bcl-2 protein family. The same effect can be elicited by a 
noncatalytic mutant of proMMP-9 and by the isolated PEX9 
domain. Thus, proMMP-9 contributes to CLL survival by a 
nonproteolytic mechanism. Dufour et al56 showed that the 
 interaction of the proMMP-9 PEX domain with CD44 acti-
vates the tyrosine kinase epidermal growth factor receptor 
(EGFR) and subsequent phosphorylation of its substrates, 
ERK, Akt, and focal adhesion kinase (FAK), resulting in 
breast carcinoma cell migration. Using xenograft models in 
NOD/SCID mice, we recently showed that the overexpression 
of proMMP-9 impairs CLL cell homing to bone marrow and 
spleen.57 A proteolytically inactive proMMP-9 mutant had a 
partial effect, indicating that both catalytic and noncatalytic 
functions were involved. Indeed, biochemical analyses dem-
onstrated that proMMP-9, likely complexed to α4β1 integrin, 
downregulates the activation of RhoAGTPase, Akt, ERK, and 
FAK, while it increases p190RhoGAP (a RhoA inhibitor) and 
PTEN (an Akt, ERK, and FAK inhibitor).57 Modulation of 
these pathways by proMMP-9 may contribute to malignant 
cell retention in lymphoid organs and CLL progression. 
MMP-9 has also recently been shown to promote rounded 
amoeboid melanoma cell migration by a noncatalytic mecha-
nism, consisting of the regulation of actomyosin contractil-
ity via CD44.58 Because actin is a substrate of MMP-9,16 a 
simple reasoning would be that this rounded amoeboid effect 
would be influenced by catalysis. However, this suggestion 
is not correct because the amoeboid cell migration was also 
observed when using a catalytically inactive MMP-9 mutant 
and also when inhibiting MMP-9 activity. This mechanism 
operates in vivo since MMP-9 expression increases during 
melanoma progression and is enriched at the invasive front 
of lesions, correlating with cell roundness. The authors pro-
pose that MMP-9 could be an amoeboid-selective marker 
for melanoma and that blocking this noncatalytic MMP-9 
function could help to reduce melanoma cell invasion and 
metastasis.58 In another study, it was found that the PEX9 
domain inhibits tumor angiogenesis and indirectly blocks the 
growth of orthotopic glioblastoma xenografts.59
Nonproteolytic functions of MMP-14
Novel functions of MMP-14 not requiring its proteolytic 
activity, but instead involving the hemopexin or cyto-
plasmic domain, have also been reported. Proteolytic and 
nonproteolytic roles of MMP-14 in different cell contexts 
have been reviewed.9,60 MMP-14 forms a complex at the 
cell surface with its physiological protein inhibitor, tissue 
inhibitor of metalloproteinase (TIMP)-2, and binding of 
TIMP-2 to MMP-14 induces cell proliferation and migration 
of MCF-7 breast carcinoma cells.61 This effect requires the 
MMP-14 cytoplasmic tail, but not its catalytic activity, and 
it involves activation of ERK1/2. Moreover, in xenograft 
models in mice, a proteolytically inactive MMP-14 mutant 
also promoted tumor growth in vivo, while a mutant lack-
ing the cytoplasmic tail was ineffective.61 A similar MEK/
ERK signaling cascade upon TIMP-2 binding to MMP-14 
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was observed in HT1080 fibrosarcoma cells, resulting in 
increased cell migration.62 These reports thus establish that 
the MMP-14–TIMP-2 interaction controls cell proliferation 
and migration by nonproteolytic mechanisms. Macrophages 
from MMP-14–/– mice have a reduced ability to invade base-
ment membranes and to infiltrate into inflammatory sites, 
and these effects are restored by MMP-14 re-expression 
on these cells.63 Importantly, this activity requires the cyto-
plasmic tail of MMP-14, but not its catalytic or hemopexin 
domains, establishing that MMP-14 regulates macrophage 
invasion and migration by dual catalytic and noncatalytic 
functions. These authors also demonstrated that MMP-14–/– 
macrophages are characterized by a reduction in adenosine 
triphosphate (ATP) concentration and in glycolytic activity.64 
The reason for this is that the cytoplasmic tail of MMP-14 
binds to HIF-1α and releases it from its specific inhibitors, 
stimulating glycolysis and ATP production by macrophages. 
Other functions for the MMP-14 cytoplasmic domain have 
also been identified. Gonzalo et al65 reported yet another new 
function for MMP-14 consisting of the control of myeloid cell 
fusion. In this case, MMP-14 induces a signaling pathway 
in which its cytoplasmic tail binds to p130Cas and increases 
Rac1 activation and lamellipodia activity, directly impacting 
cell morphology, motility, and fusion by a nonproteolytic 
mechanism. In a more recent report, Mori et al66 demonstrated 
an association between MMP-14 and β1 integrin in mam-
mary epithelial cells. This association modulates β1 integrin 
levels, activates ERK, and induces branching morphogenesis 
in collagen 1 gels and primary mammary organoids. Using 
several MMP-14 deletion mutants, these authors show that 
the transmembrane/cytoplasmic domain of MMP-14, but 
not its catalytic domain, is required for these functions. 
Collectively, these studies clearly expand the functions of 
MMPs beyond those involving substrate degradation. While 
the MMP enzymatic activity is certainly crucial to promote 
cell migration, invasion, and survival, we may conclude on 
the basis of various examples that MMPs also induce and/
or modulate the signaling pathways necessary for these 
 processes. This knowledge opens new avenues to explore and 
identify targets in MMPs outside the catalytic domain.
The hemopexin domain of MMPs  
as an emerging therapeutic target
The carboxy-terminal region of MMPs (hemopexin domain, 
PEX) has, for a long time, been recognized as an interesting 
module able to interact with several molecules and display 
multiple properties.67 Besides containing binding sites for 
TIMPs, gelatin, and other MMPs, PEX is required for MMP 
binding to cell surface receptors67 and plays an important role 
in the activation of signaling pathways, many of which have 
been described earlier. Because several of these signals are 
associated with pathological processes, the PEX domain – in 
particular, its interaction sites with cell surface receptors – 
has emerged as a novel therapeutic target in MMPs. This is 
further substantiated by the reported properties of the isolated 
PEX domain mentioned earlier for MMP-348 and MMP-9.55,59 
The PEX domain from MMP-2 also inhibits tumor growth in 
an in vivo model of mouse glioma, together with a decrease 
in angiogenesis and cell proliferation.68 Additionally, the iso-
lated murine PEX9 domain inhibits MMP-9 gelatin-binding 
activity and the invasion of melanoma cells,69 the adhesion 
and migration of colorectal cancer cells,70 as well as VEGF 
secretion, angiogenesis, and tumor growth in a glioblastoma 
animal model.59 These studies provide evidence that MMPs, 
through their PEX domain, can perform many nonproteolytic 
functions.
Crystal structure analyses71–75 were used to demonstrate 
that hemopexin domains consist of a four-bladed β-propeller 
structure (blades 1–4) (shown in Figure 2A for PEX9). The 
primary structure homology among the hemopexin domains 
of different MMPs is rather low (25%–30%),67 and this fact 
represents a major advantage when considering targeting 
this region in a particular MMP. This low homology con-
trasts with the existing higher resemblance among MMP 
catalytic domains.27 Strategies aimed to block the MMP 
hemopexin domain are already in progress. Using phage 
display analyses, Björklund et al76 identified a synthetic 
peptide  (CRVYGPYLLC) that binds to the PEX9 domain 
and inhibits the association of MMP-9 with αVβ5 integrin 
in fibrosarcoma cells. This peptide also inhibits cell migra-
tion in vitro and tumor xenograft growth in vivo. Dufour 
et al56 designed the synthetic peptides SRPQGPFL and 
NQVDQVGY, mimicking motifs in the outermost strands 
of blades 1 and 4 of PEX9, respectively. According to the 
authors, these peptides inhibited MMP-9 dimerization and the 
migration of fibrosarcoma and carcinoma cells. Additionally, 
peptide SRPQGPFL blocked the interaction of MMP-9 with 
CD44, suggesting that this sequence was involved in MMP-9 
docking at the cell surface. The same group reported similar 
findings for the hemopexin domain of MMP-14 (PEX14).77 
In this case, the synthetic peptides, MVPDPMYG and 
GYPKSALR, containing sequences in the outermost strands 
of blade 1 and blade 4, respectively, inhibited carcinoma cell 
migration, tumor metastasis, and angiogenesis. By preparing 
truncated proteins containing GST fused to structural blades 
1–2 or 3–4 of PEX9, and overlapping synthetic peptides cor-
responding to the entire PEX9 sequence, we have defined the 
PEX9 regions responsible for binding of proMMP-9 to CLL 
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Figure 2 Ribbon diagram of the monomeric hemopexin domain of MMP-9 (PeX9) showing the location of drug target sites.
Notes: (A) PeX9, similar to other PeX domains of MMPs, is composed of four structural blades surrounding a central cavity. (B) Spatial location of the P3 and P6 amino acid 
sequences within PeX9 (research originally published in The Journal of Biological Chemistry. Ugarte-Berzal e, Bailón e, Amigo-Jiménez I, Albar JP, García-Marco JA, García-Pardo 
A. A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migra tion of chronic lymphocytic leukemia (CLL) cells. 
The Journal of Biological Chemistry. 2014; 289(22):15340–15349. © the American Society for Biochemistry and Molecular Biology.79). P3 is located in blade 4 and interacts with 
α4β1 integrin; P6 is located in blade 1 and binds to CD44.79 P3 and P6 act synergistically to inhibit MMP-9-induced CLL cell adhesion and migration, thus serving as therapeutic 
peptides and simultaneously pointing to “druggable” targets in PeX9. An additional CD44-binding sequence located in the outermost strand of blade 1 has also been reported. 
(C) Diagram showing the binding sites within PeX9 of small Mw compounds mapped by in silico docking (adapted from Cancer Research, Copyright 2011;71(14):4977–4988. 
Dufour A, Sampson NS, Li J, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9, with permission from 
AACR82). As observed, both the small compounds and the P3 and P6 sequences are located in close proximity within the central cavity of PeX9. Targeting this region may 
therefore be a useful approach to control the pathogenic functions of MMP-9, particularly in cancer and inflammation.
Abbreviations: Mw, molecular weight; MMP, matrix metalloproteinase; PeX, hemopexin domain; CLL, chronic lymphocytic leukemia.
cells. Blades 1–2 are important for the interaction with CD44 
and blades 3–4 for binding to α4β1 integrin.78,79 The specific 
binding sites involved in these interactions are the sequences 
FDAIAEIGNQLYLFKDGKYW, present in blade 1 and con-
tained in peptide P6, and FPGVPLDTHDVFQYREKAYFC, 
present in blade 4 and contained in peptide P3.78,79 P6 and P3 
bind, respectively, to CD44 and α4β1 integrin (Figure 2B) 
and partially inhibit CLL cell adhesion and transendothelial 
migration. P3 also blocks the Lyn/Mcl-1 survival pathway 
elicited by proMMP-9 or GST–PEX9 upon binding to CLL 
cells.55 Importantly, the combination of P3 and P6 is syner-
gistic and results in the complete inhibition of cell adhesion 
and migration. This is in agreement with the spatial local-
ization of both peptides within the central cavity of PEX9 
(Figure 2B).78,79 The P3 and P6 sequences thus represent 
two potential targets to prevent proMMP-9 binding to CLL 
cells and subsequent pathological consequences. Peptide-
based inhibitors targeting exosites and/or both exosites and 
active sites may therefore constitute an efficient way to block 
catalytic and noncatalytic MMP activities, such as the regula-
tion of cell adhesion, migration, and signaling. The already 
identified peptides with inhibitory action mainly on MMP-9 
and MMP-14 have been recently reviewed.80
Besides the synthetic peptide strategies, in silico 
approaches are also being employed to target the MMP 
hemopexin domain. Using chemoinformatics-based analy-
ses, Kothapalli et al81 found several molecules that spe-
cifically bind to the hemopexin domain of MMP-13. This 
information helped to design drugs to inhibit this MMP, 
particularly in inflammatory disorders. In silico docking 
approaches have also served to identify two small molecules 
that selectively bind to PEX9 and inhibit tumor growth and 
metastasis without affecting the MMP-9 catalytic activity.82 
One of the compounds found in this study (compound 2) 
also blocks MMP-9 homodimerization and ERK1/2 phos-
phorylation, and the authors proposed that this is likely due 
to the inhibition of the binding of MMP-9 to CD44 and the 
subsequent activation of the EGFR–MAPK signaling path-
way.82 A similar approach was employed by Remacle et al83 
to identify a small compound that binds to the PEX domain 
of MMP-14 and represses the protumorigenic function of 
MMP-14 in a carcinoma xenograft model. Importantly, the 
docking analyses mapped the binding sites of these small 
molecule inhibitors to the central cavity of PEX9 and 
PEX14, respectively; in fact, they were in close proximity 
to the P3 and P6 sequences identified by us in PEX9 (Figure 
2C). These findings highlight the central cavity of PEX as 
a prime target in future strategies aimed to overcome MMP 
pathologic signaling functions in cancer, inflammation, and 
other disorders.
Targeting the MMP hemopexin domain is therefore 
a promising alternative to previous attempts aimed at 
blocking the catalytic activity of MMPs and, in view of 
the lower homologies of various MMP hemopexin domains 
versus catalytic domains, this has the added advantage of 
higher selectivity. Another interesting advantage comes 
from studies in which targeting the hemopexin domain 
impairs the catalytic activity of MMPs. Using phage display 
Metalloproteinases In Medicine 2015:2submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
26
García-Pardo and Opdenakker
techniques, Basu et al84 generated recombinant antibody 
fragments against PEX14 that significantly reduced the 
degradation of collagen type I by MMP-14 and inhibited 
CD44 shedding by MMP-14-expressing fibrosarcoma cells. 
These antibodies also inhibit invasion and angiogenesis 
in in vitro systems. Although it is not clear whether the 
antibody effect is directly affecting interactions with 
MMP-14 substrates or imposing structural restrictions that 
affect MMP-14 function, the results certainly highlight the 
hemopexin domain as a useful target to modulate MMP 
functions.
Conclusion
Previous attempts to block the pathological functions of 
MMPs by targeting the catalytic domain were disappoint-
ing in oncology studies and, therefore, the idea of targeting 
MMPs in invasive cancer was abandoned. The efforts to 
generate more selective inhibitors have been revitalized with 
the exosite concept in which larger areas of the catalytic 
domain are targeted with new drugs.85 Moreover, recent stud-
ies pointed to other regions of MMPs as promising targets 
to block the pathological activities of MMPs. In particular, 
the carboxy-terminal domains, both the hemopexin domain 
and the intracellular segments of MT-MMPs, have been 
studied as targets for inhibition. In these cases, the binding 
and signaling functions of MMPs, rather than their catalytic 
effects, are targeted. Two major directions are becoming 
clear in this area of research. First, membrane-bound MMPs 
(eg, MMP-14) signal through their intracellular domains by 
interaction with cytoplasmic adaptor molecules. Secondly, 
the hemopexin domain of secreted MMPs, such as MMP-347,48 
and MMP-9,55,57 activates signaling cascades by interacting 
with signaling receptors (eg, integrins) or by being part of 
oligosaccharide lectin interactions (eg, CD44 [hyaluronan 
receptor] and chondroitin sulfate proteoglycans).32 For 
both types of signaling interactions, peptides and/or small 
molecule inhibitors have been developed. These studies 
generate the necessary insights for the development of novel 
therapeutics and form a complementary research route, 
alongside catalysis inhibitors, in the fight against cancer and 
other diseases.
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